630 related articles for article (PubMed ID: 29867974)
1. Programmed Cell Death Protein 1-PDL1 Interaction Prevents Heart Damage in Chronic
Fonseca R; Salgado RM; Borges da Silva H; do Nascimento RS; D'Império-Lima MR; Alvarez JM
Front Immunol; 2018; 9():997. PubMed ID: 29867974
[TBL] [Abstract][Full Text] [Related]
2. PD1 and PDL1 molecules control suppressor activity of regulatory T cells in chronic Chagas cardiomyopathy patients.
Damasio MPS; Rocha MOC; Sousa GR; Ferreira KS; Fares-Gusmão RCG; Medeiros NI; Araujo FF; Chaves AT; Dutra WO; Correa-Oliveira R; Gomes JAS
Hum Immunol; 2019 Jul; 80(7):517-522. PubMed ID: 30853363
[TBL] [Abstract][Full Text] [Related]
3. A human type 5 adenovirus-based Trypanosoma cruzi therapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy.
Pereira IR; Vilar-Pereira G; Marques V; da Silva AA; Caetano B; Moreira OC; Machado AV; Bruna-Romero O; Rodrigues MM; Gazzinelli RT; Lannes-Vieira J
PLoS Pathog; 2015 Jan; 11(1):e1004594. PubMed ID: 25617628
[TBL] [Abstract][Full Text] [Related]
4. CCL3/Macrophage Inflammatory Protein-1α Is Dually Involved in Parasite Persistence and Induction of a TNF- and IFNγ-Enriched Inflammatory Milieu in
Gibaldi D; Vilar-Pereira G; Pereira IR; Silva AA; Barrios LC; Ramos IP; Mata Dos Santos HA; Gazzinelli R; Lannes-Vieira J
Front Immunol; 2020; 11():306. PubMed ID: 32194558
[TBL] [Abstract][Full Text] [Related]
5. Challenge of chronically infected mice with homologous trypanosoma cruzi parasites enhances the immune response but does not modify cardiopathy: implications for the design of a therapeutic vaccine.
Rosas-Jorquera CE; Sardinha LR; Pretel FD; Bombeiro AL; D'Império Lima MR; Alvarez JM
Clin Vaccine Immunol; 2013 Feb; 20(2):248-54. PubMed ID: 23254299
[TBL] [Abstract][Full Text] [Related]
6. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients.
Pérez-Antón E; Egui A; Thomas MC; Puerta CJ; González JM; Cuéllar A; Segovia M; López MC
PLoS Negl Trop Dis; 2018 May; 12(5):e0006480. PubMed ID: 29750791
[TBL] [Abstract][Full Text] [Related]
7. An Animal Model of Acute and Chronic Chagas Disease With the Reticulotropic Y Strain of
Mateus J; Guerrero P; Lasso P; Cuervo C; González JM; Puerta CJ; Cuéllar A
Front Immunol; 2019; 10():918. PubMed ID: 31105709
[TBL] [Abstract][Full Text] [Related]
8. IL-10 participates in the expansion and functional activation of CD8
Pino-Martínez AM; Miranda CG; Batalla EI; González-Cappa SM; Alba Soto CD
J Leukoc Biol; 2019 Jan; 105(1):163-175. PubMed ID: 30371945
[TBL] [Abstract][Full Text] [Related]
9. Autoimmunity in Chagas' disease. Identification of cardiac myosin-B13 Trypanosoma cruzi protein crossreactive T cell clones in heart lesions of a chronic Chagas' cardiomyopathy patient.
Cunha-Neto E; Coelho V; Guilherme L; Fiorelli A; Stolf N; Kalil J
J Clin Invest; 1996 Oct; 98(8):1709-12. PubMed ID: 8878420
[TBL] [Abstract][Full Text] [Related]
10. Endogenous CD4(+) CD25(+) regulatory T cells have a limited role in the control of Trypanosoma cruzi infection in mice.
Kotner J; Tarleton R
Infect Immun; 2007 Feb; 75(2):861-9. PubMed ID: 17101658
[TBL] [Abstract][Full Text] [Related]
11. Disease Tolerance and Pathogen Resistance Genes May Underlie
Chevillard C; Nunes JPS; Frade AF; Almeida RR; Pandey RP; Nascimento MS; Kalil J; Cunha-Neto E
Front Immunol; 2018; 9():2791. PubMed ID: 30559742
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory receptors are expressed by Trypanosoma cruzi-specific effector T cells and in hearts of subjects with chronic Chagas disease.
Argüello RJ; Albareda MC; Alvarez MG; Bertocchi G; Armenti AH; Vigliano C; Meckert PC; Tarleton RL; Laucella SA
PLoS One; 2012; 7(5):e35966. PubMed ID: 22574131
[TBL] [Abstract][Full Text] [Related]
13. Experimental Nanovaccine Offers Protection Against Repeat Exposures to
Chowdhury IH; Lokugamage N; Garg NJ
Front Immunol; 2020; 11():595039. PubMed ID: 33414785
[TBL] [Abstract][Full Text] [Related]
14. Lack of Galectin-3 Prevents Cardiac Fibrosis and Effective Immune Responses in a Murine Model of Trypanosoma cruzi Infection.
Pineda MA; Cuervo H; Fresno M; Soto M; Bonay P
J Infect Dis; 2015 Oct; 212(7):1160-71. PubMed ID: 25805753
[TBL] [Abstract][Full Text] [Related]
15. CD28 is required for T cell activation and IFN-gamma production by CD4+ and CD8+ T cells in response to Trypanosoma cruzi infection.
Martins GA; Campanelli AP; Silva RB; Tadokoro CE; Russo M; Cunha FQ; Rizzo LV; Silva JS
Microbes Infect; 2004 Nov; 6(13):1133-44. PubMed ID: 15488732
[TBL] [Abstract][Full Text] [Related]
16. Role of the PD-1/PD-L1 Pathway in Experimental
Arana Y; Gálvez RI; Jacobs T
Front Immunol; 2022; 13():866120. PubMed ID: 35812458
[TBL] [Abstract][Full Text] [Related]
17. Humoral and cellular immune response of adults from northeastern Brazil with chronic Trypanosoma cruzi infection: depressed cellular immune response to T. cruzi antigen among Chagas' disease patients with symptomatic versus indeterminate infection.
Cetron MS; Basilio FP; Moraes AP; Sousa AQ; Paes JN; Kahn SJ; Wener MH; Van Voorhis WC
Am J Trop Med Hyg; 1993 Sep; 49(3):370-82. PubMed ID: 8372959
[TBL] [Abstract][Full Text] [Related]
18. In the presence of Trypanosoma cruzi antigens, activated peripheral T lymphocytes retained in the liver induce a proinflammatory phenotypic and functional shift in intrahepatic T lymphocyte.
Meuser-Batista M; Vacani-Martins N; Cascabulho CM; Beghini DG; Henriques-Pons A
J Leukoc Biol; 2020 Apr; 107(4):695-706. PubMed ID: 32202341
[TBL] [Abstract][Full Text] [Related]
19. A therapeutic nanoparticle vaccine against Trypanosoma cruzi in a BALB/c mouse model of Chagas disease.
Barry MA; Wang Q; Jones KM; Heffernan MJ; Buhaya MH; Beaumier CM; Keegan BP; Zhan B; Dumonteil E; Bottazzi ME; Hotez PJ
Hum Vaccin Immunother; 2016 Apr; 12(4):976-87. PubMed ID: 26890466
[TBL] [Abstract][Full Text] [Related]
20. Exhausted PD-1
Gálvez RI; Jacobs T
Front Immunol; 2022; 13():866179. PubMed ID: 35720419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
